Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term follow-up study of tofacitinib in children with juvenile idiopathic arthritis
MOH_2017-03-26_000272Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Started Nov 2016; status: recruiting.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on MOH_2017-03-26_000272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-26_000272.